Akshaya Bio Inc.

Report
Akshaya Bio Inc.
Chimigen® Technology-Based
Molecular Vaccines
InnovationScan
November, 2013
Akshaya Bio Inc.
…..…………..focus is on vaccines
1
Akshaya Bio Inc.
Outline
• The Company
Management
Research Team
Collaborators
• Chimigen® Platform Technology
Unique Features
Product Pipeline
Status
• Highlights
• Contacts
Akshaya Bio Inc.
…..…………..focus is on vaccines
2
Akshaya Bio Inc.- Current
• Based in Edmonton, Alberta
 8223 Roper Road
 Currently a team of Nine, Eight Researchers (7 Ph.Ds, 1 B.Sc. 1 MBA)
• Founded in 2010
 Dendritic cell receptor-targeted vaccines
 Proprietary technology
• 16 issued patents
• 32 patents pending worldwide
 Acquired Chimigen® Technology from Paladin Labs Inc. and ViRexx
Medical Corp., (TSX, AMEX)
• External Partners in Research and Development
 NRC-IRAP, CHTD, AITF, Gates Foundation
• Unique technology platform
 Improved antigen presentation
• Rich Product Pipeline
 HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza,
Akshaya Bio Inc.
…..…………..focus is on vaccines
3
Management Team
• Satish Chandran, Ph.D
• Chief Executive Officer
• Rajan George, M.Sc, Ph.D
• President and Chief Scientific Officer
• Bruce Hirsche, QC
• General & Intellectual Property
Counsel
• Rohit George, BA, MBA
• Business Operations
Akshaya Bio Inc.
…..…………..focus is on vaccines
4
Research Team
• Allan Ma, Ph.D
• Senior Scientist, Virologist
• Dakun Wang, Ph.D
• Senior Scientist, Immunologist
• Yun Xia, Ph.D
• Cell Biologist/Immunologist
• Morris Kostiuk, Ph.D
• Biochemist/Molecular Biologist
• Gina Thede, Ph.D
• Biochemist/Molecular Biologist
• Hue Anh Luu, B.Sc
• Technologist
Akshaya Bio Inc.
…..…………..focus is on vaccines
5
Collaborators
•
•
•
•
•
•
•
•
NRC/IRAP
– Eric Swanson, Ph.D
Nuron Biotech
– HBV Vaccine License
– HCV Vaccine License Option
University of Alberta- HBV & HCV Clinical Research
– Klaus Gutfreund, M.D, Assoc. Professor, Medicine, U of A
– Mang Ma, M.D, Assoc. Professor, Medicine, U of A
VIDO/InterVac-Immunology in Animals
– Qiang Li, Ph.D
NRC-NINT-Nanoparticles
– Nils Peterson, Ph.D
CHTD/Gates Foundation
DRDC Suffield
– Les Nagata, Ph.D (Head Biotechnology Section)
NIH
– HBV & HCV
Akshaya Bio Inc.
…..…………..focus is on vaccines
6
Chimigen® Platform Technology
Novel Approach to an Established Concept
Dendritic Cell Receptor-Targeted Vaccines
Akshaya Bio Inc.
…..…………..focus is on vaccines
7
Chimigen®- A Platform Technology
Chimigen® Recombinant Molecule
6xHis
6xHis
Antigen
Antigen
CHO
IRD
CHO
Peptide Linker
Portion of CH 1
S-S
Hinge Region
S-S
S S
CHO
CH2 S S CCH2
H2
Xenotypic
(Murine) Fc
CHO
TBD
SS
SS
C H3
CH3
Peptide
Strong Intellectual Property Position
16 Issued Patents, 32 Patent Applications Pending worldwide
Akshaya Bio Inc.
…..…………..focus is on vaccines
8
Chimigen®- A Platform Technology
• Characteristics of both Antigen (Ag) and Antibody (Ab)
• Xenotypic (foreign) Ab fragment makes whole molecule
“foreign” & thus more immunogenic
• Adaptable platform
– Adaptable to disease-specific multiple molecular antigenic
epitopes
– HBV, HCV, HIV, Biodefense Applications (Alphaviruses), Pandemic
Preparedness (H5N1, H1N1), Malaria, Cancer etc.
• Designed to generate broad immune responses
– Cellular (Class I)- critical to clear virus infected & cancer cells
– Humoral (Class II)- Antibodies
• Potential use for both Prophylactic & Therapeutic
Vaccines
Akshaya Bio Inc.
…..…………..focus is on vaccines
9
Chimigen®- A Platform Technology
•
•
•
•
•
Effective at low doses (µg)
– Targets multiple cell types relevant to immune activation
– Targets multiple specific receptors on Antigen Presenting Cells
• Dendritic Cells (Fcy, Lectin Receptors)
Minimal safety concerns
– Utilizes classical antigen presentation pathway
– No added adjuvant
• Eliminates many adverse events
• Eliminates T cell sequestration, dysfunction & deletion (Nat. Med. 2013,
Lu. et al)
Ease of production and scalability
– Utilizes insect cell-based production
• Increased antigenicity through production of the chimeric molecule in
Insect Cells
• Imparts non-mammalian glycosolation; Highly immunogenic
Established purification systems
Binding and uptake through Fc and Lectin receptors
Akshaya Bio Inc.
…..…………..focus is on vaccines
10
Product Pipeline & Status
• HBV Therapeutic/Prophylactic Vaccine
• Preclinical completed (Licensed to Nuron, co-development)
• HCV Therapeutic/Prophylactic Vaccine
• Preclinical (Nuron co-development, option to license)
• HIV Prophylactic/Therapeutic Vaccine
• Discovery (CHTD-NRC-IRAP)
• Cancer Vaccine
• Discovery
• Malaria
• Late discovery stage (Gates Foundation); ready for animal studies
• Biodefense and Pandemic Applications
• Alphavirus (WEEV) Vaccine, Discovery/Preclinical
• Influenza H5 & H1
• Pre-clinical
Akshaya Bio Inc.
…..…………..focus is on vaccines
11
Akshaya’s Competitive Advantages
• Meets major unmet needs
 No vaccine/therapy available
• Efficacy, it works
 Proof of Concept established
 HBV Chronic Carriers
 Breaking Tolerance
• No Adjuvant
 Eliminates majority of the adverse reactions
 The Scare Factor
 Eliminates production of “dysfunctional CTLs”
• Re-educating the immune system
 Uses Dendritic Cell Receptor
 Natural endogenous process for uptake and presentation of
antigens & induction of broad immune responses
Akshaya Bio Inc.
…..…………..focus is on vaccines
12
Chimigen® Vaccine Highlights
Highlights
• Versatile, Adaptable Platform
• Dendritic Cell Receptor-Targeted Vaccines
• Generates broad immune responses
– Cellular (Class I)- critical to clear virus infected &
cancer cells
– Humoral (Class II)- Abs- Helps CTLs
• Proof of principle established with Chimigen® HBV
Therapeutic Vaccine
• Potential use for both Prophylactic & Therapeutic
Vaccines
• Strong Intellectual Property Position
Akshaya Bio Inc.
…..…………..focus is on vaccines
13
Contacts
• Satish Chandran, Ph.D
Rajan George, M.Sc, Ph.D
•
Chief Executive Officer
President & Chief Scientific Officer
•
•
•
•
8223 Roper Road
Edmonton
Alberta, T6E 6S4
Canada
8223 Roper Road
Edmonton
Alberta, T6E 6S4
Canada
•
Mobile: 215 896 3392
•
Email:
[email protected]
Telephone: 780 989 6705
Mobile: 780 493 1706
Email: [email protected]
Web: www.akshayabio.com
•
Web: www.akshayabio.com
Akshaya Bio Inc.
…..…………..focus is on vaccines
14
Akshaya Bio Inc.
Thank You…….
Akshaya Bio Inc.
…..…………..focus is on vaccines
15

similar documents